Advanced Filters
noise
Found 2,256 clinical trials
K Karisma Pantaleon

Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer

Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered supportive care intervention for historically underserved populations of women with metastatic breast cancer.

18 years of age Female Phase N/A
X Xichun Hu

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer

18 years of age All Phase 3
M Manju Daniel, PhD

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

This study aims to to improve physical activity and metabolic outcomes for breast cancer prevention in South Asian Indian immigrant women.

40 - 65 years of age Female Phase N/A
W Wei Li, Ph.D

Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast Cancer

Evaluate the Efficacy of Auricular Acupuncture Therapy via the Seirin Pyonex Needles in the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer

18 - 75 years of age Female Phase N/A
M Manon Chédeville, Doctoral Researcher

tDCS Intervention in Breast Cancer Survivors With and Without Obesity Reporting Cognitive Impairment

The goal of this intervention is to investigate whether transcranial Direct Current Stimulation (tDCS) can alleviate Cancer-Related Cognitive Impairment (CRCI) in breast cancer survivors, as measured by changes in brain structures and cognitive performance. To assess the efficacy of tDCS, the investigators will compare outcomes between participants receiving active stimulation …

18 years of age Female Phase N/A

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR)and RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer with Toripalimab combined with neoadjuvant chemotherapy and sequential Toripalimab monoclonal antibody, including the incidences and types of adverse …

18 - 75 years of age Female Phase 2
C Cheng Zhang, PhD

Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors

To explore the efficacy of dCBT-I therapy for chronic insomnia among breast cancer survivors in China, we propose to conduct a randomized, parallel controlled clinical study in breast cancer survivors using a smartphone Chinese application (app) "resleep". Breast cancer survivors with chronic insomnia were recruited from our Breast Disease Center …

18 years of age Female Phase N/A
J Joshua D Mitchell, M.D., FACC

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Ten to 15% of patients with breast cancer are HER2 positive, with treatment focused on targeting the HER2 receptor. Although these treatments are generally well tolerated, they are associated with an increased risk of cardiomyopathy. There are currently no treatments proven to prevent the cardiotoxicities associated with HER2-targeted therapy, but …

18 years of age All Phase 2
B Binash Afzal, PhD

Effects of Sensorimotor Training With Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a prevalent and clinically relevant side effect of chemotherapy in breast cancer patients. It occurs in 30-70% of cases. It can cause various sensory and motor symptoms. Specific exercise interventions have proven promising to target relevant symptoms. Therefore, the objective of this study is to …

30 - 65 years of age Female Phase N/A
Y Yin U Liu, M.D

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.

18 - 70 years of age Female Phase 2

Simplify language using AI